company background image

Enovis NYSE:ENOV Stock Report

Last Price


Market Cap







27 Jun, 2022


Company Financials +
ENOV fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance1/6
Financial Health3/6

ENOV Stock Overview

Enovis Corporation operates as a medical technology company worldwide.

Enovis Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enovis
Historical stock prices
Current Share PriceUS$58.99
52 Week HighUS$164.01
52 Week LowUS$54.43
1 Month Change-11.72%
3 Month Change-51.81%
1 Year Change-57.11%
3 Year Change-28.78%
5 Year Change-50.74%
Change since IPO-6.37%

Recent News & Updates

May 23

Enovis: Medtech Leftover Of Colfax With Some To Prove

Enovis has been the medtech segment which remained following the spin-off from Colfax. The standalone business has some to prove, as margins need a boost to create appeal here. I think that the valuations here are too demanding, preferring the welding ESAB business.

Shareholder Returns

ENOVUS Medical EquipmentUS Market

Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned -23.6% over the past year.

Return vs Market: ENOV underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is ENOV's price volatile compared to industry and market?
ENOV volatility
ENOV Average Weekly Movement12.7%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: ENOV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ENOV's weekly volatility has increased from 7% to 13% over the past year.

About the Company

n/a16,200Matt Trerotola

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.

Enovis Fundamentals Summary

How do Enovis's earnings and revenue compare to its market cap?
ENOV fundamental statistics
Market CapUS$3.19b
Earnings (TTM)US$85.63m
Revenue (TTM)US$4.00b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENOV income statement (TTM)
Cost of RevenueUS$2.32b
Gross ProfitUS$1.68b
Other ExpensesUS$1.59b

Last Reported Earnings

Apr 01, 2022

Next Earnings Date


Earnings per share (EPS)1.58
Gross Margin41.98%
Net Profit Margin2.14%
Debt/Equity Ratio44.6%

How did ENOV perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is ENOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENOV?

Other financial metrics that can be useful for relative valuation.

ENOV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA7.8x
PEG Ratio12.4x

Price to Earnings Ratio vs Peers

How does ENOV's PE Ratio compare to its peers?

ENOV PE Ratio vs Peers
The above table shows the PE ratio for ENOV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.7x
OMCL Omnicell
ATRC AtriCure
ITGR Integer Holdings
ENOV Enovis

Price-To-Earnings vs Peers: ENOV is good value based on its Price-To-Earnings Ratio (37.2x) compared to the peer average (45.7x).

Price to Earnings Ratio vs Industry

How does ENOV's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Earnings vs Industry: ENOV is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the US Medical Equipment industry average (34.8x)

Price to Earnings Ratio vs Fair Ratio

What is ENOV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENOV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.2x
Fair PE Ratio24x

Price-To-Earnings vs Fair Ratio: ENOV is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the estimated Fair Price-To-Earnings Ratio (24x).

Share Price vs Fair Value

What is the Fair Price of ENOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ENOV ($58.99) is trading above our estimate of fair value ($40.62)

Significantly Below Fair Value: ENOV is trading above our estimate of fair value.

Price to Earnings Growth Ratio

PEG Ratio: ENOV is poor value based on its PEG Ratio (12.4x)

Discover undervalued companies

Future Growth

How is Enovis forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENOV's forecast earnings growth (3% per year) is above the savings rate (1.9%).

Earnings vs Market: ENOV's earnings (3% per year) are forecast to grow slower than the US market (13.9% per year).

High Growth Earnings: ENOV's earnings are forecast to grow, but not significantly.

Revenue vs Market: ENOV's revenue is expected to decline over the next 3 years (-10.7% per year).

High Growth Revenue: ENOV's revenue is forecast to decline over the next 3 years (-10.7% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ENOV's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Enovis performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ENOV has a large one-off loss of $119.7M impacting its April 1 2022 financial results.

Growing Profit Margin: ENOV's current net profit margins (2.1%) are lower than last year (2.5%).

Past Earnings Growth Analysis

Earnings Trend: ENOV's earnings have grown by 9.2% per year over the past 5 years.

Accelerating Growth: ENOV's earnings growth over the past year (7.8%) is below its 5-year average (9.2% per year).

Earnings vs Industry: ENOV earnings growth over the past year (7.8%) underperformed the Medical Equipment industry 12.9%.

Return on Equity

High ROE: ENOV's Return on Equity (1.9%) is considered low.

Discover strong past performing companies

Financial Health

How is Enovis's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ENOV's short term assets ($2.3B) exceed its short term liabilities ($1.5B).

Long Term Liabilities: ENOV's short term assets ($2.3B) do not cover its long term liabilities ($2.4B).

Debt to Equity History and Analysis

Debt Level: ENOV's net debt to equity ratio (30.3%) is considered satisfactory.

Reducing Debt: ENOV's debt to equity ratio has increased from 39% to 44.6% over the past 5 years.

Debt Coverage: ENOV's debt is not well covered by operating cash flow (12.4%).

Interest Coverage: ENOV's interest payments on its debt are well covered by EBIT (5.7x coverage).

Balance Sheet

Discover healthy companies


What is Enovis's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENOV's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ENOV has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Matt Trerotola (54 yo)





Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...

CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD13.83M) is above average for companies of similar size in the US market ($USD6.87M).

Compensation vs Earnings: Matt's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: ENOV's management team is considered experienced (4.7 years average tenure).

Board Members

Experienced Board: ENOV's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.

Top Shareholders

Company Information

Enovis Corporation's employee growth, exchange listings and data sources

Key Information

  • Name: Enovis Corporation
  • Ticker: ENOV
  • Exchange: NYSE
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$3.187b
  • Shares outstanding: 54.03m
  • Website:

Number of Employees


  • Enovis Corporation
  • 2711 Centerville Road
  • Suite 400
  • Wilmington
  • Delaware
  • 19808
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.